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Background: Prior studies reported conflicting findings on the association between metabolic syndrome and
inflammatory biomarkers. We tested the cross-sectional associations between metabolic syndrome and nine
inflammatory markers.
Methods: We measured C-reactive protein, CD40 ligand, interleukin-6, intercellular adhesion molecule-1, monocyte
chemoattractant protein-1, osteoprotegerin, P-selectin, tumor necrosis factor-alpha, and tumor necrosis factor
receptor-2 in 2570 Framingham Offspring Study participants free of diabetes and cardiovascular disease at
examination 7. Metabolic syndrome was defined by National Cholesterol Education Program criteria. We performed
multivariable linear regressions for each biomarker with metabolic syndrome as the exposure adjusting for age, sex,
smoking, aspirin use, and hormone replacement. We subsequently added to the models components of the
metabolic syndrome as continuous traits plus lipid lowering and hypertension treatments. We considered P< 0.05
as statistically significant.
Results: Metabolic syndrome was present in 984 (38%) participants and was statistically significantly associated with
each biomarker (all P< 0.02) except osteoprotegerin. After adjusting for its component variables, the metabolic
syndrome was associated only with P-selectin (1.06 fold higher in metabolic syndrome, 95% CI 1.02, 1.10, p = 0.005).
Conclusions: Metabolic syndrome was associated with multiple inflammatory biomarkers. However, adjusting for
each of its components eliminated the association with most inflammatory markers, except P-selectin. Our results
suggest that the relation between metabolic syndrome and inflammation is largely accounted for by its
components.
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Obesity, insulin resistance and type 2 diabetes mellitus
have been characterized as chronic “inflammatory” states
that are associated with abnormal concentrations of
cytokines, acute-phase reactants and other inflammatory
signaling markers [1-5]. An association between meta-
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reproduction in any medium, provided the ordiabetes mellitus and cardiovascular disease also has
been described [6-8]. In addition, consistent associations
between elevated mean C-reactive protein (CRP) concen-
trations and body weight and metabolic syndrome have
been demonstrated [9-12].
According to the most recent World Health
Organization expert consultation with respect to meta-
bolic syndrome, future research should focus on further
elucidation of common metabolic pathways underlying
the development of diabetes and cardiovascular diseases
[13]. Furthermore, the shift in mean body mass index
(BMI) towards higher levels in all age and sex groups in
the US [14] and to an increased prevalence of metabolical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evaluating the association between metabolic syndrome
and inflammatory biomarkers [12].
Prior studies have examined the association of meta-
bolic syndrome to one or a few inflammatory biomar-
kers, in modest-sized cohorts reporting conflicting
findings [2,9,10,12,16]. The available literature has been
inconclusive as to whether metabolic syndrome is a bet-
ter predictor of the development of diabetes mellitus
and/or cardiovascular disease when compared to its indi-
vidual factors. Some experts have suggested that the risk
associated with the syndrome is explained by the pres-
ence of its components [17-19].
We evaluated the association between metabolic syn-
drome and a panel of nine inflammatory biomarkers in
the community-based Framingham Heart Study. The
nine biomarkers were chosen to represent different
phases and processes in inflammatory pathways as
detailed elsewhere [20,21]. Briefly, CRP is a nonspecific
acute phase reactant; interleukin-6, tumor necrosis factor
alpha, and tumor necrosis factor receptor 2 represent
cytokines; monocyte chemoattractant protein-1 contri-
butes to leukocyte recruitment; P-selectin is responsible
for leukocyte tethering; CD40 ligand contributes to cellu-
lar immunity; intercellular adhesion molecule-1 contri-
butes to leukocyte adhesion; and osteoprotegerin is a
member of the tumor necrosis factor receptor family.
We tested the hypothesis that the relation between meta-
bolic syndrome and inflammation is accounted for by
the components of the metabolic syndrome. In the pres-
ence of heterogeneity in the metabolic state among the
different BMI categories [22], we hypothesized that
knowledge of inflammatory biomarkers might help to
understand differences between ‘metabolically healthy
but obese’ and ‘metabolically obese but normal weight’
individuals.
Methods
The present cross-sectional study was conducted in
the Framingham Heart Study, a community-based ob-
servational epidemiological project. The design and
selection criteria of the Framingham Offspring study
have been described [23]. Individuals (n = 3539) who
participated at the 7th examination cycle (1998 to
2001) were evaluated in this study. Participants were
excluded for the following reasons (in order): off-site
examination (n = 206); prevalent diabetes, defined as
fasting plasma glucose ≥126 mg/dL or use of insulin
or oral hypoglycemic agents (n = 449); prevalent car-
diovascular disease, defined as a history of angina pec-
toris, coronary insufficiency, myocardial infarction,
heart failure, transient ischemic attack, stroke, or
intermittent claudication, determined by a panel of
three physicians (n = 305); missing informationregarding metabolic syndrome traits or insulin treat-
ment (n = 9). The study protocol was reviewed and
approved by the Institutional Review Board of Boston
University Medical Center; all participants gave writ-
ten consent.
Covariate assessment
The covariates were defined at examination cycle 7
through assessment of questionnaires, physicals and
laboratory tests. Current smoking status was classi-
fied by self-report of cigarette smoking during the
year prior to examination. Resting blood pressure
was measured in a seated position by the physician
using a mercury column sphygmomanometer; blood
pressure represented the average of two readings.
Hypertension was defined as systolic blood pressure
≥140 mmHg or diastolic blood pressure ≥90 mmHg
or use of antihypertensive medications. Waist cir-
cumference in centimeters was measured by trained
technicians at the umbilicus level according to a
standard protocol. BMI was defined as the indivi-
dual’s body weight divided by the height squared,
expressed in kg/m2. Obesity was defined as BMI
≥30 kg/m2. Lipid profile, plasma glucose and insulin
levels were measured from morning fasting blood
samples using standardized assays. We calculated
homeostasis model assessment insulin resistance
index (HOMA-IR) by applying the formula [(fasting
insulin)(fasting glucose)]/22.5. Insulin resistance was
considered present if the insulin resistance index
(HOMA-IR) was ≥75th percentile. Aspirin use was
defined as 3 or more doses per week.
Measurement of inflammatory and oxidative stress
marker concentrations
Fasting samples were frozen at −80° Celsius until testing.
Serum concentrations were measured for CRP, interleukin-
6, intercellular adhesion molecule-1, monocyte chemo-
attractant protein-1. Plasma concentrations were estimated
for CD40 ligand, osteoprotegerin, P-selectin, tumor necrosis
factor-alpha, and tumor necrosis factor receptor 2. CRP was
measured through high sensitivity Dade Behring BN100
nephelometer. Other biomarkers were assessed by enzyme
linked immunoassay; all intra-assay coefficients of variation
were ≤9.1%. Details regarding marker selection and mea-
surements have been reported [24].
Definition of metabolic syndrome
Metabolic syndrome was defined according to the Na-
tional Cholesterol Education Program Adult Treatment
Panel III guidelines [5] as elucidated in Table 1. Metabol-
ically healthy but obese individuals were defined as parti-
cipants with BMI ≥30 kg/m2, but without the metabolic
syndrome. Metabolically obese but normal weight
Table 1 Participant characteristics
Metabolic Syndrome
No (n=1586) Yes (n = 984)
Age, years 58 ± 9 62 ± 9
Women, % 60 52
Body mass index, kg/m2 25.9 ± 4.2 30.5 ± 5.0
Mean waist, cm 93 ± 12 106 ± 11
Systolic blood pressure, mmHg 120 ± 17 133 ± 18
Hypertension, % 22 64
Hypertension treatment, % 15 44
Current smoking, % 14 11
Triglycerides, mg/dl 101 ± 53 171 ± 91
Total/HDL cholesterol 3.5 ± 1.0 4.6 ± 1.3
Lipid treatment, % 5 27
Aspirin use, % 22 29
Hormone replacement therapy, % 20 16
Metabolic syndrome components, % (n)
Elevated waist circumference ≥102 cm in men, ≥88 cm in women 41 (655) 88 (862)
Elevated triglycerides ≥150 mg/dL 16 (248) 69 (679)
Low HDL <40 mg/dL in men, <50 mg/dL in women 11 (169) 53 (522)
High blood pressure Systolic BP ≥130, diastolic BP ≥85 mmHg or
treatment
32 (502) 79 (778)
Hyperglycemia Fasting glucose ≥100 and <126 mg/dL 17 (273) 67 (661)
Data are mean ± standard deviation and % (n). BP denotes blood pressure.
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syndrome and BMI <25 kg/m2.Statistical analyses
The inflammatory markers concentrations showed
skewed distributions and were natural log-transformed
before further analysis. We performed multivariable lin-
ear regression with biomarkers as dependent variables
adjusting for age, sex, smoking, aspirin use, and hormone
replacement therapy. In model 1, metabolic syndrome
was the key exposure. In model 2, we added adjustment
for metabolic syndrome components as continuous traits
while adjusting for age, sex, smoking, aspirin use, hor-
mone replacement, lipid lowering treatment and hyper-
tension therapy. In model 3, we examined inflammatory
biomarkers with interaction between metabolic syn-
drome and BMI: normal weight was defined as BMI
<25 kg/m2, overweight as BMI 25–29.99 kg/m2 and
obese as BMI ≥30 kg/m2. With model 4, we analyzed in-
flammatory biomarkers with the interaction between
metabolic syndrome and insulin resistance. We esti-
mated fold increment (and 95% CI) comparing adjusted
biomarker levels in groups with and without metabolic
syndrome. We considered P <0.05 as statisticallysignificant. The statistical analysis was performed with
SAS version 8.1 (SAS Institute, Cary, NC, USA).
Secondary analyses
In secondary analyses, tests for sex interaction with meta-
bolic syndrome were performed for the inflammatory bio-
markers, adjusting for age, smoking, aspirin and hormone
replacement therapy using a significance level of P< 0.01.
Results and discussion
Table 1 shows clinical characteristics of the 2570 partici-
pants. The study had 984 (38%) participants with (mean
age 62 ± 9 years, 52% women) compared to 1586 partici-
pants without (mean age 58 ± 9 years, 60% women) the
metabolic syndrome.
Regression model for the individual markers
Multiple linear regression models demonstrated highly sta-
tistically significant associations (P <0.0001) between preva-
lent metabolic syndrome and CRP, interleukin-6,
intercellular adhesion molecule-1, P-selectin, tumor necro-
sis factor-alpha, and tumor necrosis factor receptor-2,after
adjusting for age, sex, smoke, aspirin and hormone replace-
ment therapy. CD40 ligand and monocyte chemoattractant-
Table 2 Fold increments for inflammatory biomarkers comparing those with metabolic syndrome (n =984) versus those
without the metabolic syndrome (n =1586)
Biomarker Model 1† Model 2 - with additional adjustment for the





P-value Sample Size Estimate (95% CI) P-value
C-reactive protein 2555 1.82 (1.67, 1.97) <0.0001 2551 1.07 (0.96, 1.19) 0.23
CD40Ligand 2559 0.89 (0.80, 0.98) 0.02 2555 0.89 (0.77, 1.02) 0.10
Intercellular adhesion molecule-1 2557 1.05 (1.03, 1.07) <0.0001 2553 1.00 (0.97, 1.03) 0.99
Interleukin-6 2553 1.29 (1.22, 1.36) <0.0001 2549 1.02 (0.94, 1.10) 0.67
Monocyte chemoattractant −1 2517 1.03 (1.01, 1.06) 0.01 2513 0.98 (0.95, 1.02) 0.34
Osteoprotegerin 2555 1.00 (0.98, 1.02) 0.92 2551 0.99 (0.96, 1.02) 0.65
P-selectin 2558 1.11 (1.08, 1.15) <0.0001 2554 1.06 (1.02, 1.10) 0.005
Tumor necrosis factor-alpha 1948 1.10 (1.05, 1.15) <0.0001 1945 0.99 (0.93, 1.06) 0.84
Tumor necrosis factor receptor 2 2505 1.09 (1.06, 1.11) <0.0001 2501 1.00 (0.97, 1.03) 0.91
† Adjusted for age, sex, smoking, aspirin use, hormone replacement therapy.
{ Adjusted for age, sex, smoking, aspirin use, hormone replacement therapy, lipid lowering medications and hypertension treatment, as well as for the
components of the metabolic syndrome: waist circumference, triglycerides level, HDL level, systolic and diastolic blood pressure and anti-hypertensive therapy, and
fasting blood glucose.
Dallmeier et al. Diabetology & Metabolic Syndrome 2012, 4:28 Page 4 of 7
http://www.dmsjournal.com/content/4/1/281 also were nominally associated (P≤ 0.02), but osteoprote-
gerin was not associated with the metabolic syndrome. Ex-
cept for osteoprotegerin, inflammatory biomarkers showed
higher mean concentrations in participants with versus
without metabolic syndrome (Table 2, model 1).Accounting for metabolic syndrome components
Table 2 (model 2) shows the relation of the metabolic
syndrome to inflammatory biomarkers after adjusting for
the components of the metabolic syndrome. In that set-
ting, metabolic syndrome remained significantly asso-
ciated only with P-selectin (P= 0.005). Subjects with
metabolic syndrome had a 1.06 fold (i.e., 6%; (95% CI
1.02, 1.10, P = 0.005)) increase of P-selectin compared to
those without metabolic syndrome.Interaction between metabolic syndrome and BMI
Only 10% (n = 101) of individuals with metabolic syn-
drome were normal weight, 43% (n = 421) were over-
weight and 47% (n = 462) were obese (Additional file 1:
Table S1). In participants without metabolic syndrome,
the distribution was shifted to lower mean BMI (45%
normal weight, 41% overweight and 14% obese). Among
normal weight participants, 12% had the metabolic syn-
drome. Obesity was observed in 680 participants; 32%
(n = 218) were metabolically healthy but obese. Among
normal weight individuals, the metabolic syndrome was
associated with higher mean concentrations of the fol-
lowing biomarkers: CRP, intercellular adhesion molecule-
1, interleukin-6, P-selectin, tumor necrosis factor-alpha
and tumor necrosis factor receptor 2 when compared to
healthy normal weight individuals (Additional file 1:
Table S1).The interaction between metabolic syndrome and
BMI category was statistically significant for CRP
(P = 0.02). The proportional increase in CRP, compar-
ing those with to those without metabolic syndrome,
decreased across BMI categories (Figure 1). The pres-
ence of metabolic syndrome was associated with a
1.60 fold (i.e. 60%; (95% CI 1.31, 1.95 fold)) increase
of the mean CRP concentration than would be antici-
pated in normal weight individuals, with a 1.27 fold
(i.e. 27%; (95% CI 1.13, 1.43 fold)) increase among
overweight subjects, but with a non-significant 1.13
fold (i.e. 13%; (95% CI 0.96, 1.31 fold)) increment in
obese individuals (Additional file 1: Table S1).Interaction between metabolic syndrome and insulin
resistance
In individuals with metabolic syndrome 49 % had insulin
resistance, compared to 10 % in those without metabolic
syndrome The interaction between metabolic syndrome
and insulin resistance was statistically significant only for
CRP (P= 0.008). Metabolic syndrome without insulin re-
sistance was associated with a 1.67 fold (i.e. 67%; (95%
CI 1.50, 1.86 fold)) increase of mean CRP levels com-
pared to those individuals without metabolic syndrome
and insulin resistance. Among those with insulin resist-
ance, metabolic syndrome was associated with a 25%
increment (1.25 fold (95% CI 1.04, 1.51 fold)) of mean
CRP levels compared to those without the metabolic
syndrome (Additional file 2: Table S2). When evaluating
participants without metabolic syndrome, those with in-
sulin resistance had statistically significant higher mean
concentrations of CRP compared to those without insu-
lin resistance, and their levels were similar to those indi-
viduals with metabolic syndrome but without insulin
Figure 1 Geometric mean concentrations of C-reactive protein (CRP) by BMI category with/without metabolic syndrome (MetS)
obtained from the multivariable-adjusted regression model with natural log(CRP) as dependent variable adjusting for age, sex,
smoking, aspirin use and hormone replacement therapy. Whiskers extend to upper limits of two-sided 95% confidence intervals.
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with both conditions (Additional file 3: Figure S1).
Secondary analyses
The interaction of metabolic syndrome and sex was sta-
tistically significant for CRP (P< 0.0001) and tumor ne-
crosis factor receptor 2 (P= 0.002). Among women, we
observed in the presence of metabolic syndrome a statis-
tically significant 2.17 fold increment of mean CRP levels
(95% CI 1.95, 2.43), whereas in men the observed incre-
ment was 1.47 fold (95% CI 1.30, 1.65). Regarding tumor
necrosis factor receptor 2, women with metabolic syn-
drome had higher mean concentrations (fold increment
1.12, 95% CI 1.09, 1.15) compared to those without;
among men the corresponding increment was 1.05 fold
(95% CI 1.01, 1.08) (Additional file 4: Table S3).
We observed a significant association between the
metabolic syndrome and all inflammatory biomarkers
except osteoprotegerin, which is consistent with the hy-
pothesis that the metabolic syndrome is accompanied by
an inflammatory state. We report an interaction between
BMI and metabolic syndrome for CRP; in individuals
with obesity the presence of the metabolic syndrome did
not appear to be associated with additional elevation in
mean CRP concentrations. We also detected a significant
interaction for CRP in relation to the metabolic syn-
drome and insulin resistance. Among those without the
metabolic syndrome, the presence of insulin resistance
was associated with higher mean concentrations of CRP.
When evaluating metabolically obese but normal weight
individuals, we observed higher mean concentrations ofCRP, intercellular adhesion molecule-1, interleukin 6, P-
selectin, tumor necrosis factor-alpha and tumor necrosis
receptor 2 compared to healthy normal weight indivi-
duals. Our results reinforce the concept that the meta-
bolic syndrome even in the absence of obesity is
associated with an inflammatory state. Finally, we
demonstrated that adjusting for all the components of
the metabolic syndrome attenuated the association be-
tween the metabolic syndrome with all biomarkers, ex-
cept P-selectin.
The association between metabolic syndrome and
some of the inflammatory biomarkers has been exam-
ined in the past [2,9,10,12,16]. The current literature
provides evidence of elevated levels of CRP, tumor ne-
crosis factor alpha, interleukin 6 in individuals with cen-
tral fat when compared to those with normal fat
distribution [25,26]. In the same cohort at the Framing-
ham Heart Study, we demonstrated that tumor necrosis
factor alpha and tumor necrosis factor alpha receptor 2
remained associated with insulin resistance after adjust-
ing for central obesity, adiponectin and resistin [27].
Consistent with our results increased levels of P-
selectin have been described among individuals with as
compared to without the metabolic syndrome [28,29].
An increased expression of cell adhesion molecules such
as intercellular adhesion molecule-1 and P-selectin have
also been associated in a smaller cohort with increased
waist circumference, low HDL cholesterol and elevated
fasting glucose [16]. P-selectin is known to be involved
in the attachment of circulating leukocytes to the vascu-
lar endothelium, contributing to the early development
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order would be detected. It is expressed on activated
platelets as well as by endothelial cells. The secretion of
P-selectin can be induced through atherogenic factors
such as oxidized LDL. Nevertheless the association be-
tween P-selectin and the metabolic syndrome after adjust-
ing for its components although statistically significant,
warrants cautious interpretation. We may have increased
the chance of introducing false positive results by multiple
testing. The clinical significance of the reported associ-
ation merits further study.
Clinical implications and future directions
We recognize the controversy surrounding the use of the
metabolic syndrome as a diagnostic or management tool,
understanding its role as a pre-morbid condition rather
than a clinical diagnosis [13]. In this regard it has been
estimated that about one fifth of the US population ful-
fills the criteria of the metabolic syndrome [15]. Further
studies evaluating the role of the inflammatory biomar-
kers among metabolically healthy but obese and meta-
bolically obese but normal weight individuals compared
to their counterparts are needed in order to enhance our
understanding regarding the pathophysiology behind the
observed clustering of abnormal metabolic traits. We ac-
knowledge that the clinical significance of our findings is
uncertain. Further work should investigate whether in-
flammatory markers will prove useful in the early identi-
fication of individuals at risk for the development of the
metabolic traits, and whether such risk stratification will
be associated with the ability to reduce or delay the inci-
dence of associated morbidity and mortality.
Strengths and limitations
Given our cross-sectional observational design, our study
cannot prove causality. It is possible that metabolic fea-
tures lead to inflammation, or that inflammation predis-
poses to the development of metabolic perturbations, or
that a complex feedback loop exists wherein each fuels
the development and progression of the other. Alterna-
tively both inflammation and metabolic traits may be
both related to additional untested features.
Of the various available definitions for the metabolic
syndrome, we used the National Cholesterol Education
Program Adult Treatment Panel III criteria. However,
one should consider the possibility that any other avail-
able scheme to define the metabolic risk could be equally
valid and produce different results. We did not account
for the multiple testing inherent in examining 9 biomar-
kers, increasing the chance to introduce false positive
findings. Because our sample represents mostly white
individuals, the generalization of our findings to other
ethnic/racial groups is uncertain. Although we selected a
robust panel of inflammatory biomarkers, we recognizedthe limitation caused by missing information on biomar-
kers such as E-selectin, VCAM-1 or adiponectin. The
strengths of the present study includes a large,
community-based sample, a routine ascertainment of po-
tential confounders and the availability of a robust set of
inflammatory markers, using precise techniques to quan-
tify their concentrations.
Conclusions
Our study evaluated a panel of nine inflammatory bio-
markers in a moderately large-sized cohort, and supports
the hypothesis that metabolic syndrome as a construct
generally is not more than the sum of its parts with re-
spect to inflammation.
Additional files
Additional file 1: Table S1. Fold increments among the inflammatory
biomarkers when comparing those with metabolic syndrome versus
those without metabolic syndrome by BMI category.
Additional file 2: Table S2. Fold increments among the inflammatory
biomarkers when comparing those with metabolic syndrome versus
those without metabolic syndrome by presence/absence of Insulin
Resistance.
Additional file 3: Figure S1. Geometric mean concentrations of C-
reactive protein (CRP) by insulin resistance (IR) with/without metabolic
syndrome (MetS) obtained from the multivariable-adjusted regression
model with natural log(CRP) as dependent variable adjusting for age, sex,
smoking, aspirin use and hormone replacement therapy. Whiskers extend
to upper limits of two-sided 95% confidence intervals. IR defined
as≥ 75% of HOMA-IR. (p = 0.008 for interaction between metabolic
syndrome and IR).
Additional file 4: Table S3. Fold increments among the inflammatory
biomarkers when comparing those with metabolic syndrome versus
those without metabolic syndrome by Sex.
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